These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19437312)

  • 1. Randomized trial of high dose azithromycin compared to standard dosing for children with severe trachoma in Tanzania.
    Campbell JP; Mkocha H; Munoz B; West SK
    Ophthalmic Epidemiol; 2009; 16(3):175-80. PubMed ID: 19437312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-day dosing versus one-day dosing of azithromycin in children with severe trachoma in Tanzania.
    Campbell JP; Mkocha H; Munoz B; West SK
    Ophthalmic Epidemiol; 2012 Feb; 19(1):38-42. PubMed ID: 22273357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village.
    West SK; Munoz B; Mkocha H; Gaydos C; Quinn T
    Invest Ophthalmol Vis Sci; 2007 Apr; 48(4):1492-7. PubMed ID: 17389476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a Single Dose of Azithromycin for Trachoma in Low-Prevalence Communities.
    Wilson N; Goodhew B; Mkocha H; Joseph K; Bandea C; Black C; Igietseme J; Munoz B; West SK; Lammie P; Kasubi M; Martin DL
    Ophthalmic Epidemiol; 2019 Feb; 26(1):1-6. PubMed ID: 30543311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass treatment with single-dose azithromycin for trachoma.
    Solomon AW; Holland MJ; Alexander ND; Massae PA; Aguirre A; Natividad-Sancho A; Molina S; Safari S; Shao JF; Courtright P; Peeling RW; West SK; Bailey RL; Foster A; Mabey DC
    N Engl J Med; 2004 Nov; 351(19):1962-71. PubMed ID: 15525721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for ocular infection with Chlamydia trachomatis in children 6 months following mass treatment in Tanzania.
    Cajas-Monson LC; Mkocha H; Muñoz B; Quinn TC; Gaydos CA; West SK
    PLoS Negl Trop Dis; 2011 Mar; 5(3):e978. PubMed ID: 21423645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results.
    Yohannan J; Munoz B; Mkocha H; Gaydos CA; Bailey R; Lietman TA; Quinn T; West SK
    JAMA Ophthalmol; 2013 Apr; 131(4):431-6. PubMed ID: 23392481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there evidence for resistance of ocular Chlamydia trachomatis to azithromycin after mass treatment for trachoma control?
    West SK; Moncada J; Munoz B; Mkocha H; Storey P; Hardick J; Gaydos CA; Quinn TC; Schachter J
    J Infect Dis; 2014 Jul; 210(1):65-71. PubMed ID: 24446528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constant ocular infection with Chlamydia trachomatis predicts risk of scarring in children in Tanzania.
    Wolle MA; Muñoz BE; Mkocha H; West SK
    Ophthalmology; 2009 Feb; 116(2):243-7. PubMed ID: 19091415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community.
    West ES; Munoz B; Mkocha H; Holland MJ; Aguirre A; Solomon AW; Bailey R; Foster A; Mabey D; West SK
    Invest Ophthalmol Vis Sci; 2005 Jan; 46(1):83-7. PubMed ID: 15623758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chlamydial positivity of nasal discharge at baseline is associated with ocular chlamydial positivity 2 months following azithromycin treatment.
    Gower EW; Solomon AW; Burton MJ; Aguirre A; Muñoz B; Bailey R; Holland M; Makalo P; Massae P; Mkocha H; Mabey DC; West SK
    Invest Ophthalmol Vis Sci; 2006 Nov; 47(11):4767-71. PubMed ID: 17065486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete local elimination of infectious trachoma from severely affected communities after six biannual mass azithromycin distributions.
    Biebesheimer JB; House J; Hong KC; Lakew T; Alemayehu W; Zhou Z; Moncada J; Rogér A; Keenan J; Gaynor BD; Schachter J; Lietman TM
    Ophthalmology; 2009 Nov; 116(11):2047-50. PubMed ID: 19744717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised controlled trial of single-dose azithromycin in treatment of trachoma.
    Bailey RL; Arullendran P; Whittle HC; Mabey DC
    Lancet; 1993 Aug; 342(8869):453-6. PubMed ID: 8102427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation (ASANTE) Trial: Design and Baseline Characteristics.
    Ervin AM; Mkocha H; Munoz B; Dreger K; Dize L; Gaydos C; Quinn TC; West SK
    Ophthalmic Epidemiol; 2016 Dec; 23(6):347-353. PubMed ID: 27820670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocular immune responses, Chlamydia trachomatis infection and clinical signs of trachoma before and after azithromycin mass drug administration in a treatment naïve trachoma-endemic Tanzanian community.
    Ramadhani AM; Derrick T; Macleod D; Massae P; Malisa A; Mbuya K; Mtuy T; Makupa W; Roberts CH; Bailey RL; Mabey DCW; Holland MJ; Burton MJ
    PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007559. PubMed ID: 31306419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study.
    West SK; Munoz B; Mkocha H; Holland MJ; Aguirre A; Solomon AW; Foster A; Bailey RL; Mabey DC
    Lancet; 2005 Oct; 366(9493):1296-300. PubMed ID: 16214600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Number of years of annual mass treatment with azithromycin needed to control trachoma in hyper-endemic communities in Tanzania.
    West SK; Munoz B; Mkocha H; Gaydos CA; Quinn TC
    J Infect Dis; 2011 Jul; 204(2):268-73. PubMed ID: 21673038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and baseline data of a randomized trial to evaluate coverage and frequency of mass treatment with azithromycin: the Partnership for Rapid Elimination of Trachoma (PRET) in Tanzania and The Gambia.
    Stare D; Harding-Esch E; Munoz B; Bailey R; Mabey D; Holland M; Gaydos C; West S
    Ophthalmic Epidemiol; 2011 Feb; 18(1):20-9. PubMed ID: 21275593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of a single round of community mass treatment with azithromycin on disease severity and ocular Chlamydia trachomatis load in treatment-naïve trachoma-endemic island communities in West Africa.
    Last AR; Burr SE; Harding-Esch E; Cassama E; Nabicassa M; Roberts CH; Mabey DCW; Holland MJ; Bailey RL
    Parasit Vectors; 2017 Dec; 10(1):624. PubMed ID: 29282126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for ocular chlamydia after three mass azithromycin distributions.
    Ayele B; Gebre T; Moncada J; House JI; Stoller NE; Zhou Z; Porco TC; Gaynor BD; Emerson PM; Schachter J; Keenan JD
    PLoS Negl Trop Dis; 2011 Dec; 5(12):e1441. PubMed ID: 22180804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.